Martin Babler - Jun 17, 2022 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Director
Signature
/s/ Laurent Chardonnet, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Jun 17, 2022
Transactions value $
$0
Form type
4
Date filed
6/22/2022, 04:13 PM
Previous filing
May 16, 2022
Next filing
Jun 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Director Stock Option (Right to Buy) Award $0 +31.3K $0.00 31.3K Jun 17, 2022 Common Stock 31.3K $4.74 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.